PDCD1 and neoplasm: While the blockade of the PD-1/PD-L1/PD-L2 immunoregulatory axis holds promise as an immunotherapeutic approach for rare FMC subtypes, further investigations are needed, particularly examining the interplay between this pathway and the tumor microenvironment.